Literature DB >> 1320354

Some new aryl-sydnones: effects on murine tumours.

N Grynberg1, R Gomes, T Shinzato, A Echevarria, J Miller.   

Abstract

The effects of new aryl-sydnones: 3-[4-X-3-nitrophenyl]-1,2,3-oxadiazolium-5-olates, where X = Cl (SYD-1); pyrrolidino (SYD-2); piperidino (SYD-3) and morpholino (SYD-4) on the survival of mice bearing Sarcoma 180, Ehrlich carcinoma, B10MCII (Fibrous histiocytoma) and L1210 leukemia ascitic tumours, on the proliferation of cultured tumour cells and on the synthesis of DNA in L1210 leukemia were determined. SYD-1 and SYD-2 in vivo significantly enhanced the survival of S180, Ehrilich and B10MCII tumour-bearing mice. Furthermore, SYD-2 showed significant activity against L1210. SYD-3 and SYD-4 did not show antitumour activity. SYD-1, in vitro was the most cytotoxic against all the above tumour cells. All of the drugs tested inhibited thymidine uptake by L1210 cells, SYD-4 being the least active.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320354

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Effect of sydnone SYD-1 on certain functions of LPS-stimulated macrophages.

Authors:  Eduardo Luis Bizetto; Guilhermina Rodrigues Noleto; Aurea Echevarria; André Vinicius Canuto; Silvia Maria Suter Correia Cadena
Journal:  Mol Cell Biochem       Date:  2011-08-30       Impact factor: 3.396

2.  Derivatives of the triaminoguanidinium ion, 5. Acylation of triaminoguanidines leading to symmetrical tris(acylamino)guanidines and mesoionic 1,2,4-triazolium-3-aminides.

Authors:  Jan Szabo; Julian Greiner; Gerhard Maas
Journal:  Beilstein J Org Chem       Date:  2017-03-22       Impact factor: 2.883

3.  Cytotoxic effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on cell lines of human melanoma.

Authors:  A Senff-Ribeiro; A Echevarria; E F Silva; C R C Franco; S S Veiga; M B M Oliveira
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.